u/Visible-Foot-1621

Lol! These shorts just dont get it

Great time to buy buy buy!

• Patient 1: A 56-year-old man with an unmethylated WHO grade 4 tumor had three prior recurrences before enrollment. Palmer said the three-month post-treatment scan showed no identifiable tumor in the treated region, no edema around the implant area and a complete response. He said the patient had no dose-limiting toxicities, no CNS adverse events and remained symptom-free without evidence of disease progression.

Buy as much as your heart desires!

Its clearly shorts.

This bodes well for Drts.

Merck’s price tag “sweet spot” for potential deals reaches up to $15 billion, CEO Robert Davis said Thursday, as the company digests recent Terns and Cidara buyouts. But he’s not ruling out even bigger buys.

“From a size perspective, we continue to look anywhere in the $1 [billion] to $15 billion range, with that kind of being the sweet spot,” Davis said on the pharma’s quarterly earnings call on Thursday. “But as we’ve consistently said, we have the capacity to go beyond that for the right strategic deal and we will if and when we see that.”